Camber Launches Spironolactone Tablets
Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launch of Spironolactone Tablets [spir-ON-oh-LAK-tone].
Spironolactone Tablets are indicated for treatment of Heart Failure, Hypertension, Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome, and Primary Hyperaldosteronism.
For complete indications, click here.
Spironolactone Tablets are available in:
| Strength | Size |
| 25 mg | 100, 500, and 1,000 ct |
| 50 mg | 100 and 500 ct |
| 100 mg | 100 and 500 ct |
Recent articles
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class






